CVRx, Inc. (CVRX) Financial Analysis & Valuation | Quarter Chart
CVRx, Inc. (CVRX)
CVRXPrice: $9.38
Fair Value: 🔒
🔒score
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with r... more
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and com... more
Description
Shares
| Market Cap | $246.80M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Kevin Hykes |
| IPO Date | 2021-06-30 | CAGR | 0.44% |
| Employees | 206 | Website | www.cvrx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CVRX chart loading...
Fundamentals
Technicals
| Enterprise Value | $278.29M | P/E Ratio | -4.6 |
| Forward P/E | -3.97 | PEG Ratio | — |
| P/S Ratio | 210569.76 | P/B Ratio | 305130.76 |
| P/CF Ratio | -311077.77 | P/FCF Ratio | -307007.85 |
| EPS | $-2.04 | EPS Growth 1Y | -23.79% |
| EPS Growth 3Y | 1.49% | EPS Growth 5Y | -92.79% |
| Revenue Growth 1Y | 10.45% | Gross Margin | 0.85% |
| Operating Margin | -0.9% | Profit Margin | -0.94% |
| ROE | -0.99% | ROA | -0.51% |
| ROCE | -0.56% | Current Ratio | 7.63 |
| Quick Ratio | 6.72 | Cash Ratio | 5.69 |
| Debt/Equity | 1.29 | Interest Coverage | -8.8 |
| Altman Z Score | -5.58 | Piotroski Score | 3 |